symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
TPST,7.17,1.397495,6666331,104418854,0,0.17-9.77,0.43,"Tempest Therapeutics, Inc.",USD,0001544227,US87978U1088,87978U108,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.tempesttx.com,"Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.","Mr. Stephen R. Brady J.D., LLM",Healthcare,US,19,415 798 8589,7000 Shoreline Court,South San Francisco,CA,94080,,0,https://financialmodelingprep.com/image-stock/TPST.png,2012-11-12,False,False,True,False,False
